Fatty Acid Synthase Inhibitors Market

Fatty Acid Synthase (FASN) Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide. FASN is a key enzyme involved in the production of saturated fatty acids in the liver and other organs and is the only enzyme in the human body capable of converting metabolized sugars into palmitate. Palmitate is a saturated fatty acid that serves as a building block for longer chain, polyunsaturated fatty acids and can directly interact with other proteins to sustain normal cell signaling and metabolic function. The overproduction of palmitate is a critical driver of cellular metabolic dysfunction that can drive development or progression of several different diseases. In patients with NASH, increased FASN-mediated palmitate synthesis in the liver is the source of three key drivers of the disease: excess accumulation of liver fat, inflammation and fibrosis. If left untreated, these can lead to cirrhosis of the liver, liver cancer and/or liver transplantation.

Fatty Acid Synthase Inhibitors Market contains market size and forecasts of Fatty Acid Synthase (FASN) Inhibitors in Global, including the following market information:

Global Fatty Acid Synthase (FASN) Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Fatty Acid Synthase (FASN) Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Powder Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Fatty Acid Synthase (FASN) Inhibitors include Merck, Abcam, Tocris Bioscience, MedChemExpress, Sagimet Biosciences, R?D Systems and Santa Cruz Biotechnology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Fatty Acid Synthase (FASN) Inhibitors companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Fatty Acid Synthase (FASN) Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Fatty Acid Synthase (FASN) Inhibitors Market Segment Percentages, by Type, 2021 (%)

Powder

Solid

Global Fatty Acid Synthase (FASN) Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Fatty Acid Synthase (FASN) Inhibitors Market Segment Percentages, by Application, 2021 (%)

Medical

Research Laboratories

Other

Global Fatty Acid Synthase (FASN) Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Fatty Acid Synthase (FASN) Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Fatty Acid Synthase (FASN) Inhibitors revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Fatty Acid Synthase (FASN) Inhibitors revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Merck

Abcam

Tocris Bioscience

MedChemExpress

Sagimet Biosciences

R?D Systems

Santa Cruz Biotechnology